<DOC>
	<DOCNO>NCT02822222</DOCNO>
	<brief_summary>The purpose study evaluate safety RMJH-111b , include well tolerate , effect RMJH-111b blood pressure subject hypertension . The study also measure amount magnesium blood urine RMJH-111b administration evaluate body RMJH-111b ( pharmacokinetics ) .</brief_summary>
	<brief_title>Safety Study RMJH-111b Treat Essential Hypertension</brief_title>
	<detailed_description>This phase 1/2 , single center , randomize , double-blind , placebo-controlled study RMJH-111b adult subject essential hypertension . Subjects take anti-hypertensive medication undergo 7-day washout period . Subjects remain eligible washout period subject require washout ( recently diagnose previously diagnose treatment &gt; 1 week start study ) receive placebo orally twice day ( bid ) 3-day run-in period . Subjects remain eligible run-in period randomize 15:6 ( total 21 randomized subject ) receive either 440 mg RMJH-111b placebo orally bid 7-day treatment period . Follow-up assessment perform 24 hour 7 day last dose study drug . Subjects remain clinical research unit low salt ( 2.5 g/24 hour ) diet run-in period 24-hour post treatment assessment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Magnesium citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Male female , 1880 year old Diagnosed essential hypertension SBP ≥ 150 &amp; ≤ 200 mmHg &amp; DBP ≥ 95 ≤ 115 mmHg Day 1 &amp; baseline ( predose Day 4 ) Both male &amp; woman child bear potential ( WCBP ) agree use adequate contraceptive method study Willing able sign inform consent form ( ICF ) Suitable participation study opinion Investigator History myocardial infarction , congestive heart failure , stroke within 6 month Screening , evidence great 1st degree heart block myocardial damage History chronic hepatitis Uncontrolled diabetes ( hemoglobin A1C ≥ 6.5 % ) Screening Day 1 Glomerular filtration rate &lt; 60 mL/min Screening Day 1 Serum hypo hypernatremia ( ≤ 133 &amp; ≥145 meq/L ) Screening Day 1 Low serum potassium ( ≤ 3.3 meq/L ) Screening Day 1 Low total serum magnesium ( ≤ 1.3 mg/dL ) total serum magnesium great upper limit normal ( 2.5 mg/dL ) Screening Day 1 Serum uric acid &gt; 6.5 mg/dL female &gt; 7.5 mg/dL male Screening Day 1 Absence patellar reflex ( knee jerk ) Day 13 , predose Day 4 Evidence clinically significant finding Screening , runin period ( Days 13 ) , baseline ( predose Day 4 ) , opinion Investigator would pose safety risk interfere appropriate interpretation safety data Malignancy within 5 year Screening Visit ( exception basal cell squamous cell skin carcinoma ) Major surgery within four week prior Screening Presence malabsorption syndrome possibly affect drug absorption ( e.g. , Crohn 's disease chronic pancreatitis ) Presence irritable bowel syndrome , ulcerative colitis , chronic diarrhea History psychotic disorder History alcoholism drug addiction current alcohol drug use , opinion Investigator , interfere subject 's ability comply dose schedule &amp; study evaluation History illicit drug use within one year prior Screening Positive drug screen Screening Day 1 , except subject prescription drug opinion Investigator influence outcome study Positive breathalyzer test blood alcohol content Screening Day 1 Consumption five cup caffeinated beverage per day Current treatment treatment within 30 day prior first dose Study Drug ( active placebo ; Day 4 ) another investigational drug , current enrollment another clinical trial Current treatment treatment within 10 day prior first dose Study Drug ( active placebo ; Day 4 ) antihypertension medication ( Study Drug treatment period ) Current treatment treatment within 30 day prior first dose Study Drug ( active placebo ; Day 4 ) magnesiumcontaining antacid laxative , dietary supplement ( ) total daily dose magnesium great 150 mg , central nervous system depressant , neuromuscular block agent , cardiac glycoside , lithiumcontaining drug , bisphosphonates , sodium polystyrene sulfonate , tetracycline/quinolone antibiotic , antitumor necrosis factoralpha drug , phytotherapeutic/herbal/ plant derive preparation Known hypersensitivity magnesium Known hypersensitivity inactive ingredient Study Drug ( placebo active ) Positive pregnancy test Screening Day 1 , lactate Arm circumference great 42 centimeter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>essential hypertension</keyword>
	<keyword>hypertension</keyword>
	<keyword>high blood pressure</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>RMJH-111b</keyword>
	<keyword>magnesium</keyword>
	<keyword>magnesium citrate</keyword>
	<keyword>calcium channel blocker</keyword>
	<keyword>vasodilator</keyword>
	<keyword>antihypertensive agent</keyword>
</DOC>